Insider Transactions in Q1 2026 at Anaptysbio, Inc (ANAB)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 15
2026
|
Magda Marquet |
SELL
Open market or private sale
|
Direct |
11,000
-29.54%
|
$528,000
$48.48 P/Share
|
|
Jan 15
2026
|
Magda Marquet |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+34.45%
|
$286,000
$26.11 P/Share
|
|
Jan 08
2026
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,650
-7.98%
|
$160,600
$44.71 P/Share
|
|
Jan 08
2026
|
Daniel Faga President, CEO |
SELL
Open market or private sale
|
Direct |
14,281
-2.89%
|
$628,364
$44.71 P/Share
|
|
Jan 08
2026
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,210
-14.69%
|
$97,240
$44.71 P/Share
|
|
Jan 08
2026
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,515
-10.32%
|
$110,660
$44.71 P/Share
|
|
Jan 07
2026
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,525
+15.71%
|
-
|
|
Jan 07
2026
|
Daniel Faga President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
26,838
+5.16%
|
-
|
|
Jan 07
2026
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,888
+28.13%
|
-
|
|
Jan 07
2026
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,700
+21.57%
|
-
|
|
Jan 07
2026
|
Daniel Faga President, CEO |
SELL
Open market or private sale
|
Direct |
9,202
-1.93%
|
$414,090
$45.11 P/Share
|
|
Jan 07
2026
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,235
-5.67%
|
$100,575
$45.11 P/Share
|
|
Jan 07
2026
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
9,639
-15.85%
|
$433,755
$45.96 P/Share
|
|
Jan 07
2026
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,908
-9.75%
|
$85,860
$45.11 P/Share
|
|
Jan 06
2026
|
Daniel Faga President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,850
+3.61%
|
-
|
|
Jan 06
2026
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,145
+13.48%
|
-
|
|
Jan 06
2026
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,545
+22.78%
|
-
|
|
Jan 06
2026
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,245
+21.13%
|
-
|
|
Jan 05
2026
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,219
-11.24%
|
$181,417
$43.26 P/Share
|
|
Jan 05
2026
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,363
-19.01%
|
$144,609
$43.26 P/Share
|
|
Jan 05
2026
|
Daniel Faga President, CEO |
SELL
Open market or private sale
|
Direct |
15,309
-3.23%
|
$658,287
$43.26 P/Share
|
|
Jan 05
2026
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,983
-18.38%
|
$128,269
$43.26 P/Share
|
|
Jan 03
2026
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,555
+21.95%
|
-
|
|
Jan 03
2026
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,292
+31.91%
|
-
|
|
Jan 03
2026
|
Daniel Faga President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
34,677
+6.82%
|
-
|
|
Jan 03
2026
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
7,287
+30.98%
|
-
|